Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 8/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 8/20 | 0.46 |
| ▸ | WNT1 | P04628 | 6/20 | 0.46 |
| ▸ | KMO | O15229 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15542994 | 0.86 | GSK3B (0.44) | GSK3BDYRK1AWNT1KMOCA1 | |
| SCHEMBL20868849 | 0.82 | KMO (0.44) | GSK3BDYRK1AWNT1KMOKCNH2 | |
| SCHEMBL1628889 | 0.80 | MAPT (0.46) | GSK3BDYRK1AWNT1SRC | |
| SCHEMBL17806601 | 0.80 | GSK3B (0.41) | GSK3BDYRK1AWNT1CA1CA2 | |
| SCHEMBL20868458 | 0.79 | GSK3B (0.39) | GSK3BDYRK1AWNT1 | |
| SCHEMBL15729262 | 0.78 | DPP4 (0.41) | GSK3BDYRK1AWNT1CA1CA2 | |
| SCHEMBL2742892 | 0.78 | CHRNB2 (0.49) | GSK3BDYRK1AWNT1KMO | |
| SCHEMBL22053089 | 0.78 | KMO (0.44) | KMOKCNH2 | |
| SCHEMBL23559594 | 0.77 | GSK3B (0.49) | GSK3BDYRK1AWNT1KMOSRC | |
| SCHEMBL31226909 | 0.77 | GSK3B (0.49) | GSK3BDYRK1AWNT1KMOSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| WO-2016086200-A9 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2016086200-A1 | 4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | GSK3B 2555/4885DYRK1A 4494/4885WNT1 2708/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | GSK3B 2555/4885DYRK1A 4494/4885WNT1 2708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.